Global News Releases

February 2023

February 4, 2023 2/4/2023 US FDA Approves Takedas TAKHZYRO lanadelumab-flyo to Prevent Hereditary Angioedema HAE Attacks in Children 2 Years of Age and Older

February 2, 2023 2/2/2023 Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions Delivers Another Strong Quarter in FY2022 Q3

January 2023

January 24, 2023 1/24/2023 Takeda to Hold Third Quarter FY2022 Earnings Call on February 2

January 23, 2023 1/23/2023 Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

January 17, 2023 1/17/2023 Takeda Named Global Top Employer for Sixth Consecutive Year

January 11, 2023 1/11/2023 Takedas EXKIVITY mobocertinib Receives Approval from the NMPA of China Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

January 9, 2023 1/9/2023 Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

January 5, 2023 1/5/2023 Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

January 4, 2023 1/4/2023 Takeda CEO Christophe Weber to Present at JP Morgan Healthcare Conference